Pacific Point Advisors LLC Purchases New Shares in TransMedics Group, Inc. (NASDAQ:TMDX)

Pacific Point Advisors LLC purchased a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 9,000 shares of the company's stock, valued at approximately $561,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Atlas Capital Advisors Inc. bought a new stake in shares of TransMedics Group during the 4th quarter worth $31,000. Hager Investment Management Services LLC bought a new stake in shares of TransMedics Group during the 4th quarter worth $33,000. Sachetta LLC bought a new stake in shares of TransMedics Group during the 4th quarter worth $40,000. AlphaQuest LLC bought a new position in TransMedics Group during the fourth quarter valued at $52,000. Finally, Arcadia Investment Management Corp MI bought a new position in TransMedics Group during the fourth quarter valued at $72,000. Institutional investors own 99.67% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research report on Wednesday, April 23rd. Oppenheimer boosted their price target on shares of TransMedics Group from $125.00 to $130.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Piper Sandler reaffirmed an "overweight" rating and set a $125.00 price target (up previously from $105.00) on shares of TransMedics Group in a research report on Friday, May 9th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $104.00 target price on shares of TransMedics Group in a research note on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $126.70.

Insider Activity at TransMedics Group

In other TransMedics Group news, Director Edward M. Basile sold 6,000 shares of the business's stock in a transaction dated Friday, May 9th. The shares were sold at an average price of $115.63, for a total transaction of $693,780.00. Following the sale, the director now directly owns 732 shares in the company, valued at $84,641.16. This represents a 89.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David Weill sold 732 shares of TransMedics Group stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total value of $90,680.16. Following the completion of the transaction, the director now owns 12,134 shares of the company's stock, valued at approximately $1,503,159.92. This trade represents a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by insiders.

TransMedics Group Stock Performance

Shares of TransMedics Group stock traded up $0.91 during trading on Friday, hitting $124.25. 443,082 shares of the company's stock were exchanged, compared to its average volume of 1,359,384. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The business has a 50-day simple moving average of $89.57 and a 200-day simple moving average of $77.17. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37. The stock has a market capitalization of $4.20 billion, a price-to-earnings ratio of 132.18 and a beta of 1.91.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.29 by $0.41. The business had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business's quarterly revenue was up 48.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.35 EPS. On average, research analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.